Pliant Therapeutics (PLRX) Proxy filing summary

Executive summary

• The 2026 Annual Meeting will be held virtually on June 11, 2026, with voting on director elections, executive compensation, and auditor ratification.

• Stockholders of record as of April 15, 2026, are eligible to vote; proxy materials are distributed primarily via the Internet to reduce costs and environmental impact.

• The board recommends voting for all proposals, including the election of three Class III directors, approval of executive compensation, and ratification of Deloitte & Touche LLP as auditor.

Voting matters and shareholder proposals

• Proposals include electing three Class III directors, a non-binding advisory vote on executive compensation, and ratifying Deloitte & Touche LLP as auditor for 2026.

• Stockholders may submit proposals for the 2027 meeting by December 23, 2026, and must follow advance notice procedures for nominations or other business.

• Voting can be done online, by phone, by mail, or during the virtual meeting; proxies default to board recommendations if no specific choices are made.

Board of directors and corporate governance

• The board will reduce from ten to seven members after the meeting due to retirements; nominees for Class III directors are Bernard Coulie, Gayle Crowell, and Steve Krognes.

• Board committees include Audit, Compensation, Nominating and Corporate Governance, and Research and Development, with updated membership post-meeting.

• Most directors are independent per Nasdaq and SEC rules; the board separates the roles of Chairman and CEO.

• The board and committees conduct annual self-evaluations and encourage director attendance at meetings.